IT S ALL ABOUT EVIDENCE
|
|
- Camron Patrick
- 6 years ago
- Views:
Transcription
1 IT S ALL ABOUT EVIDENCE COVERAGE WITH EVIDENCE DEVELOPMENT IN CANADA DEVIDAS MENON, SCHOOL OF PUBLIC HEALTH, UNIVERSITY OF ALBERTA 2012 CADTH SYMPOSIUM, Ottawa, 17 April 2012
2 What s this all about? Experience in other jurisdictions How well have these schemes worked? What are the challenges? How could we do this in Canada?
3 Available health care resources should be used in a way that improves health of populations Uncertainties about clinical benefit and cost challenge decision-making on access, coverage and reimbursement System incentives should encourage innovations for improving health care Research findings and coverage decisions are closely linked (need the former in order to optimize the latter) Collecting data offers one way of acquiring evidence to reduce uncertainty and increase the probably of making a good decision
4 THE UNCERTAINTY GAPS 1) Clinical benefit - Safety and effectiveness over the short and long term when used in the real world 2) Value for money - cost effectiveness or utility placed on health gains and the opportunity costs of those gains 3) Adoption and diffusion - Eligible patients, anticipated uptake rates, whether the technology is a replacement for an existing technology or an addition to current practice 4) Affordability - Overall cost to the health system, taking into account any savings that may be realized
5 KEY QUESTIONS How do we develop a decision or policy framework that better deals with uncertainty? How do we decide when to invest in data collection to inform a definitive coverage decision? How do we decide if we have enough evidence to make a coverage decision?
6 ACCESS WITH EVIDENCE DEVELOPMENT (AED) Conditional or provisional funding decision that links payment to the collection and analysis of additional information needed to make a definitive funding decision Risk of exposing patients to ineffective or harmful technologies Risk of non-coverage depriving patients of access to beneficial technologies
7 ADVANTAGES Patients gain access to technologies that would otherwise not be funded Generates clinical evidence to inform future patients and providers Payers share responsibility for generating evidence they need to make fair decisions when market forces have failed to do so Industry gains limited reimbursement to bridge the period between regulatory approval and public funding May reduce perceived biases against promising, but less well proven technologies May help to improve population health by ensuring better use of scarce resources
8 WHAT DO WE KNOW ABOUT AED? Not new Many different names (e.g., field evaluations, 3-C funding, coverage with evidence development (CED), Only in Research (OIR)) Has been applied in several countries Examples from the Australia, Canada and the United States
9 RESULTS: INTERNATIONAL EXAMPLES OF COVERAGE AS PART OF A STUDY Country Technology Indication Uncertainty Australia Endovascular aortic aneurysm repair (EVAR) Deep brain stimulation (DBS) Positron Emission Tomography (PET) Abdominal aortic aneurysm Parkinson s disease unresponsive to pharmaceutical therapy Diagnosis and staging of various cancers Safety; long term clinical effectiveness Safety; long term clinical effectiveness; cost Safety; clinical effectiveness; costeffectiveness Netherlands Spinal Cord Stimulation (SCS) Chronic non-oncological pain Technology adoption & diffusion; cost Autologous bone marrow transplant (BMT) Advanced breast cancer Safety; clinical effectiveness Lung volume reduction surgery (LVRS) Emphysema Safety; clinical effectiveness; cost Carotid artery angioplasty+ stenting (CAS) Prevention of stroke due to carotid artery disease Safety; clinical effectiveness United States Positron Emission Tomography (PET) Suspected dementia Clinical effectiveness Positron Emission Tomography (PET) Diagnosis and staging of various cancers Clinical effectiveness Implantable Cardioverter Defibrillator Prevention of sudden cardiac death Safety; clinical effectiveness Long term home oxygen treatment Patients with severe COPD Clinical effectiveness; cost Artificial hearts Biventricular end stage heart disease Safety; clinical effectiveness
10 COVERAGE AS PART OF A STUDY: TYPE OF EVIDENCE DEVELOPMENT RCT Registry Case series Autologous BMT (US) EVAR (Australia) DBS (Australia) LVRS (US) Long term home oxygen treatment PET for cancer (Australia) Spinal Cord Stimulation (SCS) (Netherlands) Carotid angioplasty (US) PET for dementia (US) PET for cancer (US) Implantable Cardioverter Defibrillators Artificial hearts
11 COVERAGE AS PART OF A STUDY: OTHER CHARACTERISTICS Scheme management and implementation 1) University-based, academic units 2) Non-profit, publicly funded research institutes (e.g., NIH) 3) Professional societies (e.g., American College of Cardiology) Funding 1) Payer funds everything 2) Industry funds technology; payer funds service; non-industry organization funds data collection 3) Industry funds technology; payer funds service; non-industry organization funds data collection 4) Payer funds technology and service; non-industry organization funds data collection
12 COVERAGE AS PART OF A STUDY: OTHER CHARACTERISTICS Time investment - Several AEDS incomplete - From date announced to decision based on results: 5½ yrs (2-11 yrs) - Time invested in organizing and planning AEDs varies 1) Political factors 2) Stakeholder buy-in 3) Complexity of study design 4) Technology characteristics
13 EVAR AUSTRALIA August 1997: Medical Services Advisory Committee (MSAC) asked to undertake a review of EVAR February 1999: MSAC review of EVAR completed; Concluded that safety and long term outcomes of the procedure are not clear and informed consent protocol must be formulated explore data collection with the view of obtaining the data required MSAC recommended linking funding to collection of information on all procedures performed; Also recommended collecting information on any open surgical repairs (OSR) performed over same time period 1999: Australian Government Department of Health and Ageing agreed to fund national audit (registry) to be overseen by the Australian Safety and Efficacy Register of New Interventional Procedures Surgical (ASERNIP-S) November May 2001: Information collected on 961 EVAR patients; Information also collected on some OSR patients
14 EVAR AUSTRALIA 2007: Results of audit reported to MSAC - 54% of patients were deemed suitable for OSR, 93% of procedures considered technical successes, 4% of patients required additional endovascular procedures, 2% of patients had EVAR converted to OSR, and 60% were still alive after 5 years of follow-up MSAC recommended that EVAR be publicly funded Minister endorsed recommendation 2009: New registry on EVAR announced
15 EVAR AUSTRALIA Issues that emerged: 1) Contract with ASERNIP-S not signed until most of the procedures had been performed 2) New and acceptable data set for open procedures needed 3) Difficult getting surgeons to use and complete repetitive data collection form 4) Recognized differences in baseline characteristics between OSR and EVAR patients, which would make it impossible to draw any conclusions on the effectiveness of EVAR, relative to open repair
16 COVERAGE AS PART OF A STUDY HOW WELL HAS IT WORKED? Definitive coverage decision consistent with AED results Technology EVAR DBS PET - cancer SCS Autologous BMT LVRS CAS PET - dementia PET - cancer ICD Home oxygen Artificial hearts Yes No Unable to assess
17 LESSONS LEARNED 1. AED can facilitate access to technologies that would otherwise not be funded 2. AED schemes could generate evidence needed to make fair decisions when market forces/commercial interests have failed to collect such evidence 3. AED schemes offer manufacturers limited reimbursement to bridge the period between regulatory approval and introduction into routine, publicly funded practice 4. Implementation of AED as a policy option can be scientifically and politically complex
18 5. Without careful consideration of study design, it may not answer the questions it was set up to address 6. Considerable upfront investment of time and resources may be needed (managing conflicts of interest, determining outcome measures that all stakeholder groups are agreeable to, stopping points, etc.) 7. Costs can be significant, so there is a need to consider whether the costs of investing in an AED are offset by savings anticipated as a result of collecting the evidence needed to fill the uncertainty
19 SO WHERE DOES THAT LEAVE US? 1. AED might be a suitable option when there is a health technology which a payer is considering funding, but a review shows that there are significant uncertainties for a policy decision to be made. 2. AED to date has not been universally successful, mainly because there has not been a systematic and considered approach to its development and implementation.
20 3. In Ontario, there is a field evaluation program which has reviewed a number of new and existing technologies. 4. In Quebec, there appear to have been hospital-based studies in which health technologies have been provided with a condition that additional evidence be collected. 5. In Alberta, the government has commissioned the development of a provincial AED framework
21 The 2004 Health Technology Strategy 1.0 recommendation on Field Evaluations and Infostructure: 1.That a coordinated Field Evaluation system be established to collect primary research data on new and experimental technologies where data needed for decision-making is insufficient. 2.That Canada's health information resources and infostructure be developed and leveraged to guide innovation, health quality, and diffusion of health technology. 3.That common health quality indicators be used to track the performance of Field Evaluations wherever possible.
A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION. Vascular Implant Surveillance & Interventional Outcomes Network
A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION Vascular Implant Surveillance & Interventional Outcomes Network Philip P. Goodney, MD, MS Chair, Research Advisory Committee
More informationOHTAC Recommendation
OHTAC Recommendation of Abdominal Aortic Aneurysms for Low Surgical Risk Patients Presented to the Ontario Health Technology Advisory Committee in October, 2009 January 2010 Background In 2005, the Ontario
More informationQuality Measures MIPS CV Specific
Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from
More informationThe Policymakers Perspective: Making Health Technology Assessment Relevant
The Policymakers Perspective: Making Health Technology Assessment Relevant Ontario Ministry of Health and Long-Term Care CCOHTA HTA Symposium April 25 & 26, 2005 Ottawa 1 The Ontario Health Care System
More informationCOVERAGE WITH EVIDENCE DEVELOPMENT
COVERAGE WITH EVIDENCE DEVELOPMENT OVERVIEW AND USE TO PROMOTE BIOMARKER DEVELOPMENT IOM National Cancer Policy Forum Sean Tunis, MD, MSc November 10, 2014 CED DEFINITION AND PURPOSE Reimbursement that
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Quality ID #259: Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post Operative
More informationAccess to newly licensed medicines. Scottish Medicines Consortium
Access to newly licensed medicines Scottish Medicines Consortium Modifiers The Committee has previously been provided with information about why the SMC uses modifiers in its appraisal process and also
More informationPanel Value Frameworks for Cancer Therapies: Are they Useful in the Context of Canadian Health Technology Assessments and Reimbursement Decisions?
Panel Value Frameworks for Cancer Therapies: Are they Useful in the Context of Canadian Health Technology Assessments and Reimbursement Decisions? 2017 CADTH Symposium Ottawa, April, 24th, 2017 Reiner
More informationDr Hugh Dixson Departments of Nuclear Medicine & Ultrasound and Gastroenterology Bankstown Hospital Sydney, Australia
Dr Hugh Dixson Departments of Nuclear Medicine & Ultrasound and Gastroenterology Bankstown Hospital Sydney, Australia Fee for service unregulated fees, mostly unlimited services Public hospitals Public
More informationKey Trends for Ambulatory Surgery Centers in 2018
Key Trends for Ambulatory Surgery Centers in 2018 Don Phalen Vice President Business Development, Regent Surgical Health Mark Murphy Chief Strategy Officer, St Joseph s Hospital MOVING TOWARDS VALUE-BASED
More informationThe Society for Vascular Surgery Patient Safety Organization: Use of A Quality Registry for Practice Improvement
The Society for Vascular Surgery Patient Safety Organization: Use of A Quality Registry for Practice Improvement Georgia Vascular Society Adam W. Beck, MD, FACS September 9, 2017 Disclosures No relevant
More informationCanada s Long Journey Toward An Orphan Drug Policy
Canada s Long Journey Toward An Orphan Drug Policy DURHANE WONG-RIEGER, PHD PRESIDENT CANADIAN ORGANIZATION FOR RARE DISORDERS September 15, 2011 Components of Canadian Plan for Rare Disorders Definition
More informationDrugs for Rare Disorders
Drugs for Rare Disorders A CASE FOR NATIONAL PHARMACARE THAT LEAVES NO ONE BEHIND Disclosures WIDOWER WHOSE SPOUSE DIED WITHOUT A DIAGNOSIS FATHER OF AN ADULT CHILD WITH A RARE DISORDER CO-FOUNDER & PRESIDENT,
More informationA simple test can detect early signs of heart disease, but insurance does not not cover it.. Coronary calcium scan finds early signs of
12-2-2013 A simple test can detect early signs of heart disease, but insurance does not not cover it.. Coronary calcium scan finds early signs of heart disease. Does medicare cover cardiac calcium score.
More informationMinistry of Health and Long-Term Care. Palliative Care. Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW
Chapter 1 Section 1.08 Ministry of Health and Long-Term Care Palliative Care Follow-Up on VFM Section 3.08, 2014 Annual Report RECOMMENDATION STATUS OVERVIEW # of Status of Actions Recommended Actions
More informationFiscal Year (FY) 2019 Hospital Inpatient Proposed Rule Interventional Cardiology, Peripheral Interventions & Rhythm Management
Fiscal Year (FY) 2019 Hospital Inpatient Proposed Rule Interventional Cardiology, Peripheral Interventions & Rhythm Management On April 24, 2018, the Centers for Medicare & Medicaid Services (CMS) released
More informationRESEARCH AND OUTCOMES: WHY ARE THEY IMPORTANT TO O&P?
RESEARCH AND OUTCOMES: WHY ARE THEY IMPORTANT TO O&P? AOPA FUTURES CONFERENCE Sam Liang January 11 th, 2015 Disclaimer: The views, observations and opinions I express in this presentation are being made
More informationREGULATION AND HTA OF MEDICAL DEVICES IN EU: WHAT CAN WE LEARN?
REGULATION AND HTA OF MEDICAL DEVICES IN EU: WHAT CAN WE LEARN? Rosanna Tarricone, PhD Associate Dean, Government Health and Non Profit Division Issue Panel Opportunities and challenges in international
More informationOur Specified Illness Benefit Is Now Even Better.
Our Specified Illness Benefit Is Now Even Better. Now Covering 47 Specified Illnesses 20 Partial Payment Illnesses Enhancements to our Specified Illness Benefit We have made enhancements to our Specified
More information2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Measure #347 (NQF 1534): Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non- Ruptured Infrarenal Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital National Quality Strategy Domain:
More informationRegistry Assessment of Peripheral Interventional Devices (RAPID)
Registry Assessment of Peripheral Interventional Devices (RAPID) Adding Data Sources May 2, 2018 W. Schuyler Jones, MD Duke Clinical Research Institute Duke Heart Center Disclosures Research Grants: Agency
More informationCancer prevention and control in the context of an integrated approach
SEVENTIETH WORLD HEALTH ASSEMBLY A70/A/CONF./9 Agenda item 15.6 25 May 2017 Cancer prevention and control in the context of an integrated approach Draft resolution proposed by Brazil, Canada, Colombia,
More informationView Report Details. Global Aortic Aneurysm Market: Trends and Opportunities ( )
View Report Details Global Aortic Aneurysm Market: Trends and Opportunities (2014-2019) View Report Details Scope of the Report The report titled Global Aortic Aneurysm Market: Trends and Opportunities
More informationPRE-ASSESSMENT. Living Donor Liver Transplantation
No. 24 Oct 2003 Before decides to undertake a health technology assessment, a pre-assessment of the literature is performed. Pre-assessments are based on a limited literature search; they are not extensive,
More informationAdvancing Health Economics, Services, Policy and Ethics
Economics, personalized health care and cancer control Stuart Peacock Canadian Centre for AppliedResearch incancer Control (ARCC) School of Population and Public Health, University of British Columbia
More informationMultiple Criteria HTA Into Practice Local HTA Program. Innovation. Presenter: Paule Poulin, PhD CREATE OR DIE!
Multiple Criteria HTA Into Practice Local HTA Program Innovation CREATE OR DIE! Presenter: Paule Poulin, PhD Authors: P. Poulin, L. Austen et al., Health Technology & Innovation Department of Surgery Calgary
More informationChronic Pain Management Services in Newfoundland and Labrador. Provincial Chronic Pain Management Working Group. Discussion Document
Chronic Pain Management Services in Newfoundland and Labrador Provincial Chronic Pain Management Working Group Discussion Document May 2008 Table of Contents PAGE 1. BACKGROUND 2 2. INTRODUCTION 2 Why
More informationEuropean Experience and Perspective on Assessing Value for Oncology Products. Michael Drummond Centre for Health Economics, University of York
European Experience and Perspective on Assessing Value for Oncology Products Michael Drummond Centre for Health Economics, University of York Outline of Presentation The European landscape on access to
More informationThe cost of cancer treatment
The cost of cancer treatment Lieven Annemans Ghent University Lieven.annemans@ugent.be January 2016 What s the problem? those prices are too high the budgets will explode these drugs offer survival benefit
More informationThe Role of Comparative Effectiveness in Health Reform
The Role of Comparative Effectiveness in Health Reform Vivian H. Coates, Vice President ECRI Institute National Congress 0n Health Reform 23 rd September, 2008 Washington, DC 1 2007 ECRI Institute What
More informationPalliative Care Quality Standard: Guiding Evidence-Based, High-Quality Palliative Care in Ontario Presented by: Lisa Ye, Lead, Quality Standards,
Palliative Care Quality Standard: Guiding Evidence-Based, High-Quality Palliative Care in Ontario Presented by: Lisa Ye, Lead, Quality Standards, Health Quality Ontario Candace Tse, Specialist, Quality
More informationOncology HTA: Canada versus UK experiences. Isabelle Chabot PhD ARCC Conference - Toronto, 12 May 2014
Oncology HTA: Canada versus UK experiences Isabelle Chabot PhD ARCC Conference - Toronto, 12 May 2014 Disclosure I worked on this analysis while a full-time employee at Pfizer. I am now the Principal at
More informationAbdominal aortic aneurysm: diagnosis and management
National Institute for Health and Care Excellence Draft for consultation Abdominal aortic aneurysm: diagnosis and management Evidence review T: Effectiveness of endovascular aneurysm repair compared with
More informationDOUBLE YOUR AMBULATORY PLATFORM
KEY STRATEGIES TO DOUBLE YOUR AMBULATORY PLATFORM BY 2020 Chris Bishop CEO OUTPATIENT EXPANSION Healthcare market is at a tipping point Innovators are committing significant resources to outpatient growth
More informationAccess to cancer drugs: The role for a stakeholder alliance?
Access to cancer drugs: The role for a stakeholder alliance? John Zalcberg Co-Chair, Cancer Drugs Alliance (CDA) Disclosures Research support, travel support and honoraria from a wide variety of pharmaceutical
More informationIssue Brief. Lumbar Fusion Surgery in California: Volumes, Costs, Length of Stay, Surgical Complications, and Insurance Reimbursement
BERKELEY CENTER FOR HEALTH TECHNOLOGY Issue Brief Lumbar Fusion Surgery in California: Volumes, Costs, Length of Stay, Surgical Complications, and Insurance Reimbursement The Berkeley Center for Health
More informationCHILD ENDS HERE HOMELESSNESS. 3 Year Strategic Plan Inn from the Cold 3 Year Strategic Plan
CHILD HOMELESSNESS ENDS HERE 3 Year Strategic Plan 2018-2021 a LET S HELP CHILDREN MORE Over the last 20 years, the Inn on our shelter, sanctuary and healing has grown from a grassroots organization to
More informationIntroduction. Summary A LOOK AT CAR-T THERAPIES MARCH 2018 LEUKEMIA AND LYMPHOMA CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY
MARCH 2018 Introduction LEUKEMIA AND LYMPHOMA This review focuses on two types of B-cell cancers: childhood B-cell acute lymphoblastic leukemia (B-ALL), and aggressive B-cell non-hodgkin s lymphoma (NHL)
More informationMaking EvidEncE RElEvant on ta R i o he a lt h t Ec hno logy a dv isory c omm i t t EE & t he MEdic a l a dv isory secre ta R i at
Making Evidence Relevant ontario health Technology advisory Committee & the medical advisory secretariat Making Evidence Relevant Ontario s Approach to Health Technology Assessment New technologies are
More informationReduction in cardiovascular related adverse events following active sac management with Nellix vs. EVAR: Are there biological advantages?
February 1, 2018 Reduction in cardiovascular related adverse events following active sac management with Nellix vs. EVAR: Are there biological advantages? Patrick Berg M.D. Marienhospital Kevelaer Germany
More informationOntario s New Colorectal Cancer Screening Program. OHA May 15, 2007
Ontario s New Colorectal Cancer Screening Program OHA May 15, 2007 Outline The Context Facts About Colorectal Cancer Research and Background Information The CRC Screening Program Average Risk Screening
More informationDENOMINATOR: Patients aged 18 and older with infrarenal non-ruptured endovascular AAA repairs
Measure #347 (NQF 1534): Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital National Quality Strategy Domain: Patient
More informationA1. Does your government have a formal, written diabetes policy or strategy?
Survey of Diabetes Programs and Services in Canada Canadian Diabetes Association Diabetes Progress Report A1. Does your government have a formal, written diabetes policy or strategy? Yes. In October 2002,
More informationHealth Disparities Research
Health Disparities Research Kyu Rhee, MD, MPP, FAAP, FACP Chief Public Health Officer Health Resources and Services Administration Outline on Health Disparities Research What is a health disparity? (DETECT)
More informationNational Cardiovascular Data Registry
National Cardiovascular Data Registry Young and Early Career Investigators ACC/AGS/NIA Multimorbidity in Older Adults with Cardiovascular Disease Workshop Ralph Brindis, MD MPH Senior Medical Officer,
More informationSUBMISSION TGA CONSULTATION: INCENTIVES FOR INNOVATION PROTECTION MECHANISMS FOR EVIDENCE-BASED, PRE-ASSESSED COMPLEMENTARY MEDICINES JUNE 2018
SUBMISSION TGA CONSULTATION: INCENTIVES FOR INNOVATION PROTECTION MECHANISMS FOR EVIDENCE-BASED, PRE-ASSESSED COMPLEMENTARY MEDICINES JUNE 2018 The science of integrative medicine INTRODUCTION The Expert
More informationNHAA Submission to the Consultation: Reforms to the regulatory framework for complementary medicines: Assessment pathways, March 2017
NHAA Submission to the Consultation: Reforms to the regulatory framework for complementary medicines: Assessment pathways, Submitted by the Naturopaths and Herbalists Association of Australia National
More informationCorporate Medical Policy
Corporate Medical Policy Endovascular Therapies for Extracranial Vertebral Artery Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: endovascular_therapies_for_extracranial_vertebral_artery_disease
More informationNew Delhi Declaration
New Delhi Declaration on High Blood Pressure Thirty-first Meeting of Ministers of Health of Countries of the WHO South-East Asia Region 10 September 2013, New Delhi, India We, the Health Ministers of
More informationHPV vaccination policies in Slovenia
HPV vaccination policies in Slovenia Country: Slovenia Partner Institute: Institute of Public Health of the Republic of Slovenia, Ljubljana Survey no: (12) 2008 Author(s): Tit Albreht Health Policy Issues:
More information6 Opportunities for Improving Pathways to Market: A Global Perspective on Dementia
6 Opportunities for Improving Pathways to Market: A Global Perspective on Dementia Raj Long Senior Regulatory Officer Bill & Melinda Gates Foundation Director Dementia Integrated Development UK HMG World
More informationClinical Policy: Total Artificial Heart Reference Number: CP.MP.127
Clinical Policy: Reference Number: CP.MP.127 Effective Date: 12/16 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationWorld Molecular Imaging Society (WMIS) Comment on Proposed Decision Memorandum for Positron Emission Tomography (CAG-00065R2)
January 11, 2013 Director, Coverage and Analysis Group Centers for Medicare & Medicaid Services 7500 Security Blvd Baltimore, MD 21244 By Online Submission RE: World Molecular Imaging Society (WMIS) Comment
More informationCOMMISSIONING POLICY
COMMISSIONING POLICY Endovascular Repair of Abdominal Aortic Aneurysm (EVAR) for patients with a higher perioperative mortality risk Specialty Vascular Surgery Distribution list All Worcestershire GP Practices
More informationMAGNETIC RESONANCE IMAGING (MRI) AND COMPUTED TOMOGRAPHY (CT) SCAN SITE OF CARE
UnitedHealthcare Commercial Utilization Review Guideline MAGNETIC RESONANCE IMAGING (MRI) AND COMPUTED TOMOGRAPHY (CT) SCAN SITE OF CARE Guideline Number: URG-13.01 Effective Date: February 1, 2019 Table
More information3.04. Immunization. Chapter 3 Section. Background. Ministry of Health and Long-Term Care
Chapter 3 Section 3.04 Ministry of Health and Long-Term Care Immunization Background Immunization with vaccines can reduce or eliminate the prevalence of many infectious diseases and therefore help maintain
More informationLivaNova Investor Day
LivaNova Investor Day TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR) Paul Buckman General Manager, TMVR September 14, 2017 Safe Harbor Statement Certain statements in this presentation, other than purely
More informationINPATIENT REIMBURSEMENT PROSPECTUS
2018 CARDIOVASCULAR SERVICE LINE INPATIENT REIMBURSEMENT PROSPECTUS Increasing financial risk to U.S. health care providers, including physicians and hospitals, has been centered on outcomes-based modifiers
More informationPersonalized Medicine*: a health economist s view
Personalized Medicine*: a health economist s view Lieven Annemans Ghent University Lieven.annemans@ugent.be * or stratified, or targeted, or precision,.. Grimbergen, November 2014 1 We need to stimulate
More informationMentis Cura November
Mentis Cura November 29 2012 www.mentiscura.com New Facts on Alzheimer s Death rank nr. 2-5 in western countries Fastest growing disease in: Cost Incedence Death rate People with Alzheimer s 2012 36 million
More informationUpdated: 26 August 2010
Australian Technical Advisory Group on Immunisation (ATAGI) Updated advice on the use of pandemic and seasonal influenza vaccines in children
More informationCFS MYPoW Chair Proposal on the HLPE work in 2018
Open Ended Working Group (OEWG) Multi-Year Programme of Work (MYPoW) Document No: CFS OEWG- MYPoW/2016/06/20/01 CFS OEWG-MYPoW Meeting # 02 Date: 20 June 2016 Time: 9.30-12.30 Location: Lebanon Room, FAO
More informationThe Silent Disease Inquiry into Hepatitis C in Australia
Australian Government response to the House of Representatives Standing Committee on Health report: The Silent Disease Inquiry into Hepatitis C in Australia November 2016 LIST OF ABBREVIATIONS AHPPC Australian
More informationIPAC date: May of 13
National Institute for Health and Care Excellence IP685/3 Transcatheter aortic valve implantation (transcatheter aortic valve replacement) for aortic stenosis Consultation Comments table IPAC date: May
More informationSeptember 2017 A LOOK AT PARP INHIBITORS FOR OVARIAN CANCER. Drugs Under Review. ICER Evidence Ratings. Other Benefits. Value-Based Price Benchmarks
September 2017 Drugs Under Review ICER s report reviewed the clinical effectiveness and value of olaparib (Lynparza, AstraZeneca), rucaparib (Rubraca, Clovis Oncology), and niraparib (Zejula, Tesaro),as
More informationThe first step to Getting Australia s Health on Track
2017 The first step to Getting Australia s Health on Track Heart Health is the sequential report to the policy roadmap Getting Australia s Health on Track and outlines a national implementation strategy
More informationNATIONAL MARROW DONOR PROGRAM. Creating Connections. Saving Lives. Fran Rabe
Creating Connections. Saving Lives. National Marrow Donor Program (NMDP) Screening of International Donors Fran Rabe FDA Liaison Meeting January 4, 2007 U.S. Importation of Peripheral Blood Stem Cells
More informationFY2015 Proposed Hospital Inpatient Rule Summary
FY2015 Proposed Hospital Inpatient Rule Summary Cardiac Rhythm Management (CRM) Electrophysiology (EP) Interventional Cardiology (IC) Peripheral Intervention (PI) On April 30, 2014, the Centers for Medicare
More informationPatient-Centered Oncology Payment: Payment Reform to Support Higher Quality, More Affordable Cancer Care (PCOP)
Patient-Centered Oncology Payment: Payment Reform to Support Higher Quality, More Affordable Cancer Care (PCOP) May 2015 Summary Overview The American Society of Clinical Oncology (ASCO) has devoted considerable
More informationCardiovascular Disease and Commercial Motor Vehicle Driver Safety. Physical Qualifications Division April 10, 2007
Federal Motor Carrier Safety Administration Executive Summary Cardiovascular Disease and Commercial Motor Vehicle Driver Safety Presented to Physical Qualifications Division April 10, 2007 Prepared by:
More informationMinister s Opioid Emergency Response Commission Recommendations to the Minister Updated July 5, 2018
The Minister s Opioid Emergency Response Commission was established May 31, 2017 to support the Government of Alberta s urgent response to the opioid crisis. As part of its mandate, the Commission is responsible
More informationAdult Cardiology Clinical Privileges
Name: Effective from / / to / / Initial privileges (initial appointment) (reappointment) Renewal of privileges All new applicants should meet the following requirements as approved by the governing body,
More informationNew Paradigms in Thoracic. Accommodate Advances in Cardiovascular Surgical Therapy. A.J. Carpenter, MD, PhD Professor of Thoracic Surgery
New Paradigms in Thoracic Surgical Training to Accommodate Advances in Cardiovascular Surgical Therapy A.J. Carpenter, MD, PhD Professor of Thoracic Surgery University i of ftexas Health hscience Center,
More informationMonitoring of Regional Cerebral Blood Flow Using an Implanted Cerebral Thermal Perfusion Probe Archived Medical Policy
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationThe extended timeframe associated with being listed on the CCSL;
13 October 2017 The Hon. Angus Taylor, MP Assistant Minister for Cities and Digital Transformation Parliament House CANBERRA ACT 2600 Email: Angus.Taylor.MP@aph.gov.au Dear Assistant Minister Certified
More informationThe Micro Level. HTA Into Practice at the Local Clinical Network Level. Presenter: Paule Poulin, PhD. Alberta Health Services
The Micro Level HTA Into Practice at the Local Clinical Network Level Presenter: Paule Poulin, PhD Authors: P. Poulin, T. Schuler & L. Austen Surgery Clinical Network Alberta Health Services 2012 CADTH
More informationCurrent treatment of Aortic Aneurysms and Dissections. Adam Keefer, MD, FACS Sean Hislop, MD, FACS
Current treatment of Aortic Aneurysms and Dissections Adam Keefer, MD, FACS Sean Hislop, MD, FACS Patient 1 69 year old well-educated man with reoccurring pain in his upper abdomen and a pulsatile mass.
More informationmidostaurin should be extended to patients who are deemed fit to receive intensive induction and consolidation, regardless of age.
midostaurin should be extended to patients who are deemed fit to receive intensive induction and consolidation, regardless of age. perc deliberated on the toxicity profile of midostaurin and noted that
More informationINSERT COMPANY LOGO HERE
2013 2014 INSERT COMPANY LOGO HERE 2014 North American 2013 North Positron American Emission SSL Tomography Certificate (PET) Imaging Technology Product Innovation Leadership Leadership Award Award Industry
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Drug-eluting balloon angioplasty versus non-stenting balloon angioplasty for peripheral arterial disease of the lower limbs [Cochrane Protocol]
More informationFifth report of Committee A
SIXTY-EIGHTH WORLD HEALTH ASSEMBLY (Draft) A68/73 26 May 2015 Fifth report of Committee A (Draft) Committee A held its twelfth and thirteenth meetings on 25 May 2015 under the chairmanship of Dr Eduardo
More informationSecond Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1
Second Quarter and First Half 2011 Conference Call 29 July, 2011 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationEvidentiary and Decision Making Challenges in the Context of Rare Diseases Provincial Program Perspective
Evidentiary and Decision Making Challenges in the Context of Rare Diseases Provincial Program Perspective Brent Fraser Director, Drug Program Services Ontario Public Drug Programs Ministry of Health and
More informationConsolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults
FINAL Consolidated Comprehensive Research Plan: Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder in Adults April 29 th, 2015 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca info@odprn.ca
More informationMarket Access in Hepatitis C Learnings From HIV
Market Access in Hepatitis C Learnings From HIV Allan F. Miranda Ph.D., MBA. Therapeutic Lead Immunology and Virology- Government Affairs and Market Access Our CREDO Throughout our global organization
More informationReport by the Comptroller and. SesSIon January Improving Dementia Services in England an Interim Report
Report by the Comptroller and Auditor General HC 82 SesSIon 2009 2010 14 January 2010 Improving Dementia Services in England an Interim Report 4 Summary Improving Dementia Services in England an Interim
More informationAccess to clinical trial information and the stockpiling of Tamiflu. Department of Health
MEMORANDUM FOR THE COMMITTEE OF PUBLIC ACCOUNTS HC 125 SESSION 2013-14 21 MAY 2013 Department of Health Access to clinical trial information and the stockpiling of Tamiflu 4 Summary Access to clinical
More informationGAVI, THE VACCINE ALLIANCE
#vaccineswork GAVI, THE VACCINE ALLIANCE Natasha Bilimoria December 2016 National Academy of Sciences www.gavi.org 1 ABOUT GAVI Gavi s mission: to save children s lives and protect people s health by increasing
More informationrisks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial.
risks. Therefore, perc agreed that the reimbursement criteria should match the eligibility criteria of the SELECT trial. perc considered input from one patient advocacy group indicating that patients value
More informationCost-effectiveness of endovascular abdominal aortic aneurysm repair Michaels J A, Drury D, Thomas S M
Cost-effectiveness of endovascular abdominal aortic aneurysm repair Michaels J A, Drury D, Thomas S M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationHEART DISEASE. Six actions the next Australian Government must take to tackle our biggest killer: National Heart Foundation of Australia 2016
Six actions the next Australian Government must take to tackle our biggest killer: HEART DISEASE National Heart Foundation of Australia 2016 NATIONAL HEART FOUNDATION OF AUSTRALIA 1 Contents The challenge
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 6 March 2007 Gap Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions éclairées
More informationOHTAC Recommendation: Twenty-Four-Hour Ambulatory Blood Pressure Monitoring in Hypertension. Ontario Health Technology Advisory Committee
OHTAC Recommendation: Twenty-Four-Hour Ambulatory Blood Pressure Monitoring in Hypertension Ontario Health Technology Advisory Committee May 2012 Background Hypertension in Canada Hypertension occurs when
More informationA New Treatment Paradigm Outside-In
A New Treatment Paradigm Outside-In 2 2013 Mercator MedSystems OneMedForum Jan 8, 2013 Outside-In Response: Signal Amplification Signal convection Signal amplification Modified from Michel 2007, ATVB 3
More informationSwiss National Strategy on Open Access
Swiss National Strategy on Open Access Preamble In a letter dated 4 December 2015, the State Secretariat for Education, Research and Innovation (hereinafter SERI) commissioned swissuniversities to elaborate,
More informationTHE NATIONAL QUALITY FORUM
THE NATIONAL QUALITY FORUM National Voluntary Consensus Standards for Patient Outcomes Table of Measures Submitted-Phase 1 As of March 5, 2010 Note: This information is for personal and noncommercial use
More informationImproving Radiotherapy in NSW: answering the tough questions
Improving Radiotherapy in NSW: answering the tough questions In 2009, Cancer Council NSW produced two reports related to radiotherapy services in our State. Firstly, a report titled Improving Radiotherapy:
More informationOHTAC Recommendation
OHTAC Recommendation Robotic-Assisted Minimally Invasive Surgery for Gynecologic and Urologic Oncology Presented to the Ontario Health Technology Advisory Committee in August 2010 December 2010 OHTAC Recommendation:
More information